Skip to main content

Historic opportunity to tackle drug-resistant TB demands fast response

War in Gaza:: find out how we're responding
Learn more

Geneva, 19 March 2013 —If measures to tackle multidrug-resistant tuberculosis (MDR-TB) are not significantly stepped up, including addressing barriers that prevent both research into better drug combinations and treatment scale up, MDR-TB rates will continue to increase worldwide and a historic opportunity to improve abysmal cure rates will have been squandered, medical humanitarian organisation Médecins Sans Frontières (MSF) warned today. Two new drugs effective against MDR-TB must be used to make treatment much shorter, more effective and less toxic. This demand is among others made by people living with the disease and MSF medical staff from around the world in a public manifesto launched today.

Read the ‘Test me, treat me’ manifesto and see who signed it at: 

Treating multi drug resistant TB and HIV/AIDS in Manipur, India
Local staff nurse draws blood from MDRTB patient Seikholien, 45, for laboratory testing. Churchandpur, Manipur, India, 24 October 2012.
Sami Siva

“We have been waiting for half a century for new drugs that are effective against tuberculosis. Must we wait another fifty years to seize this historic opportunity to improve and roll out treatment for drug-resistant TB?” said Dr Erkin Chinasylova, TB doctor for MSF in

Swaziland. “Getting better treatment is beyond urgent, but we are not seeing anything like the level of prioritisation required to make this a reality.”

MSF projects are seeing unprecedented numbers of people with MDR-TB around the world, with drug resistance found not only among patients who have previously failed TB treatment but also in patients newly diagnosed with TB – a clear sign that MDR-TB is being transmitted in its own right in the communities in which we work.

Left untreated, the infectious disease is lethal, but treatment today puts people through two years of excruciating side effects, including psychosis, deafness and constant nausea, with painful daily injections for up to eight months. Barely half of people get cured.

After close to five decades of insufficient research and development into TB, two new drugs - bedaquiline and delamanid - have recently been or are about to be approved. Research is urgently needed to determine the best way to use these new drugs so that treatment can be made shorter and more effective, and rolled out to treat the growing number of people with MDR-TB. People on MDR-TB treatment and their caregivers from around the world outline these and other demands in the Test me, treat me manifesto, and urge others to join their call for urgent action.

“It’s 2013 and I’m beginning a fourth year of living with TB, when I should be in my fourth year at university,” said Phumeza Tisile, a 22-year-old woman who receives treatment for extensively drug-resistant TB from MSF in Khayelitsha, South Africa, and is one of the signatories of the manifesto. “I’ve swallowed around 20,000 pills and received over 200 daily painful injections since I started treatment in June 2010, and the drugs have left me deaf. I wish I could take just two tablets a day for a month or so and be cured.”

The number of people receiving MDR-TB treatment globally remains shockingly low, at less than one in five. Greater political and financial support from the international community is needed to address this gap.

“Right when TB should be the global priority, the trend we’re seeing is that it is being deprioritised.  This is unacceptable,” said Dr Manica Balasegaram, executive director of MSF’s Access Campaign.

The Global Fund provides about 90 per cent of international support for TB, but it has recently reduced the share going to the disease. Ahead of a key replenishment meeting later this year, donors must ensure the Fund is adequately financed so that countries have the support they need to strengthen the MDR-TB response. With better treatment on the way, affected countries should scale up efforts to diagnose and treat MDR-TB today, so that robust programmes are in place once the new drugs are introduced. 

See MSF infographics on TB – length of treatment, side effects, access to treatment etc – at  

Up Next
Report 17 September 2013